Central nervous system aspergillosis in allogeneic XXXX recipients.

@entity1 @entity1667 @entity8 @entity410 @entity57 @entity2379 @entity1269 @entity2381 @entity2132 @entity3
@entity3 ( @entity3 ) is relatively common in allogeneic @entity8 ( @entity8 ) recipients. Although lungs are the most common site, central nervous system (CNS) involvement is also observed in this setting. We have retrospectively studied 14 cases of CNS @entity2381 found in a cohort of 455 allogeneic @entity8 recipients (incidence 3%). All @entity1 , except one, had experienced @entity2132 treated with high-dose @entity1667 , and eight @entity1 (57%) had also received ATG. The median time to the diagnosis of CNS @entity2381 was 124 days (range 49-347 days) from @entity8 . @entity57 had been diagnosed earlier in four @entity1 (29%). The most common initial symptoms of CNS @entity2381 were @entity410 , @entity1269 , and mental alteration. Neuroradiological studies revealed single (two @entity1 ) or multiple (seven @entity1 ) focal lesions of 0.2-9 cm in diameter. Despite clinical suspicion in many @entity1 , a confirmed diagnosis of CNS @entity2381 was made during life in only one @entity1 . A total of 12 @entity1 (86%) received @entity2379 . Despite therapy, all @entity1 died 0-27 days (median seven days) after the initial CNS symptoms. CNS @entity2381 is not uncommon in allogeneic @entity8 recipients. Clinical manifestations are usually dramatic and progress quickly. Earlier and more effective treatment of @entity3 is needed to prevent dissemination of infection into the CNS.
